II. Indications
- Severe active Rheumatoid Arthritis refractory to DMARDs
- Plaque Psoriasis
- Crohns Disease
III. Contraindications
- Chronic or acute infection
- Concurrent use of Interleukin-1 Receptor Antagonist
IV. Mechanism: Monoclonal Antibody
- Human antitumor Necrosis Factor alpha
- Similar to Infliximab and Etanercept
V. Preparations
- Humira (Adalimumab)
- Original prototype drug with release in 2003 for Rheumatoid Arthritis, with expanding indications since
- Multiple biosimilar agents pending release in 2023
- Abrilada
- Amjevita
- Cyltezo
- Hulio
- Hyrimoz
- Yusimry
VI. Dosing
- Every other week: 40 mg SC
VII. Adverse Effects
-
Immunosuppression
- Use caution in any patient prone to infection
- Headache
- Rash
- Hypertension
- Hyperlipidemia
- Injection site inflammation
- Gastrointestinal upset
VIII. Cost
- Two 40 mg vials: $1200 (in 2003)
IX. References
- (2003) Lexi-Comp Drug Database
Images: Related links to external sites (from Bing)
Related Studies
| humira (on 6/21/2023 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| HUMIRA 40 MG/0.8 ML SYRINGE | $3,121.27 each | |
| HUMIRA PEN 40 MG/0.8 ML | $3,119.47 each | |
| HUMIRA PEN CROHN'S-UC-HS STARTER 40 MG/0.8 ML | $3,115.25 each | |
| HUMIRA PEN PSORIASIS-UVEITIS-ADOL HS STARTER 40 MG/0.8 ML | $3,115.30 each | |
| HUMIRA(CF) 40 MG/0.4 ML SYRINGE | $3,123.51 each | |
| HUMIRA(CF) PEN 40 MG/0.4 ML | $3,121.75 each | |
| HUMIRA(CF) PEN 80 MG/0.8 ML | $6,721.88 each | |